XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary
Alberta
T2P 4K9
Canada
Tel: 1-403-455-7727
Website: http://www.xortx.com/
Email: info@xortx.com
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.
LEADERSHIP:
CEO: Allen Davidoff
CLINICAL TRIAL:
95 articles with XORTX Therapeutics Inc.
-
XORTX Announces Type D Meeting with FDA to be held May 1, 2023
3/14/2023
XORTX Therapeutics Inc. is pleased to announce submission of a Type D meeting request to the US Food and Drug Administration (“FDA”).
-
XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones
2/7/2023
XORTX Therapeutics Inc. is pleased to provide a summary of Company’s progress in 2022 and milestones planned for 2023.
-
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical TrialSafe and Effective Dosing of XORLO™
1/19/2023
XORTX Therapeutics Inc. is pleased to announce positive topline results from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial.
-
XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression
1/3/2023
XORTX Therapeutics Inc. is pleased to announce the submission of a Patent Cooperation Treaty patent application seeking international patent protection for the patent entitled “Compositions and Methods for Diagnosis, Treatment and Prevention of Kidney Disease”.
-
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
12/19/2022
XORTX Therapeutics Inc. is pleased to announce the completion of dosing in the XRX-OXY-101 pharmacokinetics bridging study (the “Study”).
-
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney Expansion
12/8/2022
XORTX Therapeutics Inc. is pleased to announce new proof of concept data demonstrating, in a second study, the effectiveness of xanthine oxidase inhibition (“XOI”) produced by the Company’s proprietary oral oxypurinol formulation, XORLO TM.
-
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics StudyXRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial
11/28/2022
XORTX Therapeutics Inc. is pleased to announce the successful screening and enrollment of the last remaining subjects into the XRX-OXY-101 Bridging Pharmacokinetics Study.
-
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
11/25/2022
XORTX Therapeutics Inc. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550 since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.
-
With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.
-
XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer
11/16/2022
XORTX Therapeutics Inc. is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer.
-
XORTX Presents New Proof of Concept Data at American Society of Nephrology
11/3/2022
XORTX Therapeutics Inc. is pleased to announce the presentation of a peer-reviewed abstract to be presented November 4, 2022 at the American Society of Nephrology Annual Conference – Kidney Week.
-
XORTX Announces Participation at Upcoming Investor Conferences - November 03, 2022
11/3/2022
XORTX Therapeutics Inc. announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences.
-
XORTX Receives Further No Objection Letter from Health Canada
10/26/2022
XORTX Therapeutics Inc. is pleased to announce receipt of a further no objection letter from Health Canada regarding the Company’s ongoing XRX-OXY101 clinical bridging pharmacokinetics study.
-
XORTX Announces Closing of US$5 Million Public Offering
10/7/2022
XORTX Therapeutics Inc. announces the closing of an underwritten public offering of: 1,400,000 common share units, with each Common Share Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of US$1.00 per Common Share Unit.
-
XORTX Announces US$5 Million Public Offering
10/4/2022
XORTX Therapeutics Inc. announces the pricing of an underwritten public offering of: 1,400,000 common share units, with each Common Share Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of US$1.00 per Common Share Unit.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
9/19/2022
XORTX Therapeutics Inc. is pleased to announce completion of the previously announced Type B Pre-phase 3 meeting with the US Food and Drug Administration (“FDA”) held on September 16, 2022.
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study
8/22/2022
XORTX Therapeutics Inc. is pleased to announce positive topline results from its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2– (“Part 2”) showing a substantial increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with food compared to the fasted state.
-
Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.